

Sister Study Breast Cancer Outcomes and Hormone Receptor Status as of Data Release 5

	N (total =2,865)	%
Breast Cancer Subtype for 1st Diagnosis		
Invasive	2,134	74.5
Invasive-ductal	1,516	52.9
Invasive-lobular	185	6.5
Invasive-mixed	142	5.0
Invasive-other/unknown ²	291	10.1
In situ	711	24.8
In situ-ductal	599	20.9
In situ-lobular	86	3.0
In situ-mixed	12	0.4
In situ-other/unknown ³	14	0.5
Invasiveness unknown ⁴	20	0.7
Stage at Diagnosis for 1st Diagnosis		
0	627	25.0
I	1,250	49.9
II	478	19.1
III	131	5.2
IV	21	0.8
Unknown, missing, cannot stage	358	
Estrogen Receptor (ER) Status for 1st Breast Cancer Diagnosis		
Positive	2029	84.2
Negative	375	15.6
Borderline	5	0.2
Unknown, missing, not performed	456	
Progesterone Receptor (PR) Status for 1st Breast Cancer Diagnosis		
Positive	1,664	71.5
Negative	658	28.3
Borderline	6	0.2
Unknown, missing, not performed	537	
HER2 Amplification Status for 1st Breast Cancer Diagnosis		
Positive	256	13.0
Negative	1,672	85.3
Borderline	33	1.7
Unknown, missing, not performed	904	
Combined ER, PR, HER2 Status		
Triple negative	202	10.7
Triple positive	126	6.7
Mixed positive and negative	1,552	82.6
Unknown, missing, not performed	985	
Incident Breast Cancer Cases by Race/Ethnicity⁵		
Non-Hispanic White	2,471	86.3
Non-Hispanic Black	206	7.2
Hispanic	104	3.6
Other	83	2.9

Age at Breast Cancer Diagnosis

Under 50 years of age	372	13.0
50-64	1,424	49.9
65 and older	1,055	37.0
Missing	14	

¹ Data release 5 (July 2016) includes outcomes from follow-up phases that had closed as of Aug 22, 2015

² Includes inflammatory, Paget's disease, Phyllodes tumor, and NOS, unknown

³ Includes Paget's disease, and NOS, unknown

⁴ Includes ductal and NOS, unknown tumors, and in situ-occult tumors

⁵ Includes invasive, in situ, and breast cancer of unknown invasiveness, precedence given to Hispanic ethnicity first, then Black race